{"id":"W2981212934","doi":"10.1016/j.eururo.2019.09.024","title":"Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma Europe; Astellas Pharma","keywords":"Mirabegron; Medicine; Overactive bladder; Tolterodine; Nocturia; Solifenacin; Urology; Placebo; Adverse effect; Internal medicine; Urination; Clinical trial; Urinary system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02284854,0.0008820078,0.005373496,0.002238508,0.000504197,0.002474183,0.001509352,0.001396772,0.002757107],"category_scores_gemma":[0.03385065,0.0008022861,0.005672236,0.004804232,0.0006360615,0.001638642,0.001627534,0.001050016,0.0004083178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001205645,"about_ca_system_score_gemma":0.002141786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001361237,"about_ca_topic_score_gemma":0.003130247,"domain_scores_codex":[0.9685529,0.01589353,0.006608441,0.004716585,0.003552219,0.0006761962],"domain_scores_gemma":[0.9514633,0.0151556,0.02478521,0.004215705,0.002888017,0.001492091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2236665,0.001035354,0.622814,0.01046509,0.101169,0.0003721505,0.0004619076,0.001250625,0.00182266,0.0002348713,0.003469033,0.03323881],"study_design_scores_gemma":[0.03224892,0.01117339,0.8978413,0.000912325,0.04988866,0.0006505031,0.0002890411,0.001871536,0.0006214145,0.0002413143,0.004120187,0.0001414999],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9396824,0.02677091,0.002272219,0.0004025329,0.00009194442,0.00274735,0.02646056,0.00009125988,0.00148083],"genre_scores_gemma":[0.9612287,0.002897929,0.002273321,0.0004965897,0.0001411395,0.002880361,0.02973422,0.00003889437,0.0003087705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02284854,"threshold_uncertainty_score":0.1208361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03355257858904147,"score_gpt":0.3502665604275806,"score_spread":0.3167139818385392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}